32 completed, 8 unknown, 5 recruiting, 4 terminated. 51 Phase 1, 15 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 51 | Completed 32, Unknown 8, Recruiting 5, Terminated 4, Withdrawn 2 |
| Phase 2 | 15 | Completed 7, Recruiting 3, Unknown 2, Withdrawn 2, Terminated 1 |
Follow Heart Valve Diseases: new trials by email Literature Review of Heart Valve Diseases trials Research Report on Heart Valve Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The REValve Clinical Trial an Evaluation Of the ReValve Palmetto Valve for the Replacement of the Native Mitral VaLVE ReValve System - Mitral Regurgitation | Phase 1 | Recruiting | ReValve Solutions Inc. | 20 | 2026-09-01 | 2026-09-29 |
| Application of [68Ga]Ga-NI-FAPI-04 PET/CT Imaging in Fibroblast Activation Protein Related Diseases Injection of 68Ga-NI-FAPI - Tumor, Cardiovascular Diseases | Phase 1 / Phase 2 | Recruiting | Peking Union Medical College Hospital | 30 | 2025-12-17 | 2026-03-11 |
| Safety and Pharmacokinetics Study of HRS-1893 Tablets in Healthy Subjects and Those With Impaired Kidney Function HRS-1893 - Hypertrophic Cardiomyopathy | Phase 1 | Completed | Shandong Suncadia Medicine Co., Ltd. | 24 | 2025-02-11 | 2025-09-10 |
| Effect of Verapamil Tablets on the Pharmacokinetic of HRS-1893 Tablets in Healthy Subjects HRS-1893 tablet, Verapamil tablet - Obstructive Hypertrophic Cardiomyopathy | Phase 1 | Completed | Shandong Suncadia Medicine Co., Ltd. | 14 | 2024-04-26 | 2024-06-06 |
| A Trial of HS-10511 in Healthy Subjects HS-10511 Tablets, HS-10511 Tablets Placebo - Hypertrophic Cardiomyopathy | Phase 1 | Unknown | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 96 | 2024-01-31 | 2024-01-18 |
| Multi-center, Open-label, Single-ascending Dose Study of Safety and Tolerability of TN-201 in Adults With Symptomatic MYBPC3 Mutation-associated HCM TN-201 - Hypertrophic Cardiomyopathy | Phase 1 / Phase 2 | Recruiting | Tenaya Therapeutics | 30 | 2023-08-10 | 2026-03-19 |
| A Trial of HRS-1893 in Healthy Volunteers and Patients With Obstructive Hypertrophic Cardiomyopathy HRS-1893, Placebo - Obstructive Hypertrophic Cardiomyopathy | Phase 1 | Completed | Shandong Suncadia Medicine Co., Ltd. | 76 | 2023-06-05 | 2024-10-30 |
| Feasibility Trial of the F2 Filter and Delivery System for Embolic Protection During TAVR F2 filter and delivery system - Aortic Stenosis | Phase 1 | Completed | EnCompass Technologies, Inc. | 31 | 2023-04-29 | 2026-10-30 |
| A Study to Evaluate the Effects of Mavacamten in Healthy Participants Mavacamten - Healthy Participants | Phase 1 | Completed | Bristol-Myers Squibb | 84 | 2023-02-20 | 2023-10-12 |
| A Study to Evaluate the Effects on the Single-Dose Drug Levels of Mavacamten in Healthy Participants Mavacamten - Healthy Participants | Phase 1 | Completed | Bristol-Myers Squibb | 158 | 2022-05-16 | 2022-11-21 |
| Effect of Anesthetics on Troponin I and ะก-reactive Protein Propofol, Isoflurane, Sevoflurane - Mitral Valve Insufficiency, Aortic Valve Insufficiency | Phase 1 | Completed | Astana Medical University | 255 | 2021-11-30 | 2023-06-05 |
| Study Evaluating the Pharmacokinetics of Mavacamten in Healthy Adult Chinese Subjects Mavacamten - Hypertrophic Cardiomyopathy | Phase 1 | Completed | LianBio LLC | 45 | 2021-10-31 | 2024-07-25 |
| Safety, Tolerability and Pharmacokinetics Study of CK-3773274 CK-3773274, Placebo - Obstructive Hypertrophic Cardiomyopathy, Healthy Adult Subjects | Phase 1 | Completed | Corxel Pharmaceuticals | 28 | 2021-04-10 | 2025-01-24 |
| The Effects of Sevoflurane, Isoflurane and Propofol During Cardiac Surgery Propofol, Isoflurane, Sevoflurane - Coronary Artery Disease, Mitral Valve Insufficiency | Phase 1 | Completed | Astana Medical University | 89 | 2021-01-22 | 2023-01-25 |
| Use of Phenylephrine for Assessment of Mitral Regurgitation Severity Mydfrin - Mitral Regurgitation | Phase 1 / Phase 2 | Recruiting | Montefiore Medical Center | 35 | 2020-12-01 | 2025-07-20 |
| A Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CT-G20 in Subjects With Obstructive Hypertrophic Cardiomyopathy CT-G20, Placebo - Cardiomyopathy, Hypertrophic Obstructive | Phase 1 | Terminated | Celltrion | 23 | 2020-10-23 | 2023-03-02 |
| The HALT Biomarker Study Proteomics Analysis - Aortic Stenosis, Hypo-attenuated Leaflet Thickening | Phase 1 | Recruiting | Massachusetts General Hospital | 300 | 2020-06-22 | 2021-11-10 |
| Neochordae Technique in Mitral Valve Repair adjustable neochordae Technique - Mitral Valve Prolapse, Mitral Regurgitation | Phase 1 | Unknown | National Heart Institute, Egypt | 30 | 2020-03-02 | 2020-03-09 |
| Gene Therapy for Male Patients With Danon Disease (DD) Using RP-A501; AAV9.LAMP2B RP-A501 - Danon Disease | Phase 1 | Completed | Rocket Pharmaceuticals Inc. | 7 | 2019-04-17 | 2026-10-06 |
| A Single and Multiple Ascending Dose Study of CK-3773274 in Healthy Adult Subjects CK-3773274 - Granules in Capsule, Placebo - Granules in Capsule, CK-3773274 - Tablets - Symptomatic Obstructive Hypertrophic Cardiomyopathy, Healthy Subjects | Phase 1 | Completed | Cytokinetics | 114 | 2018-12-04 | 2025-01-24 |
Showing 20 of 51. Sign in to see all of them.
Cardiomyopathy, Hypertrophic (19) · Mitral Valve Insufficiency (16) · Heart Failure (7) · Aortic Valve Stenosis (5) · Coronary Artery Disease (4) · Heart Diseases (4) · Cardiomyopathies (3) · Cardiovascular Diseases (3) · Hypertrophy (3) · Mitral Valve Prolapse (3) · Aortic Valve Insufficiency (2) · Atrial Fibrillation (2) · Gastroesophageal Reflux (2) · Heart Defects, Congenital (2)
Cardiovascular Diseases (48) · Heart Diseases (47) · Aortic Valve Disease (26) · Aortic Stenosis, Subvalvular (19) · Aortic Valve Stenosis (19) · Cardiomyopathies (17) · Pathological Conditions, Signs and Symptoms (11) · Pathologic Processes (8) · Vascular Diseases (7) · Ventricular Outflow Obstruction (6) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (5) · Myocardial Ischemia (5) · Arterial Occlusive Diseases (4) · Arteriosclerosis (4)
MYK-461 (5) · Isoflurane (2) · Mutagenesis, Insertional (2) · Propofol (2) · Sevoflurane (2) · 5-chloro-2-(5-chlorothiophene-2-sulfonylamino)-N-(4-(morpholine-4-sulfonyl)phenyl)benzamide (1) · Acetylcysteine (1) · Adrenergic beta-Antagonists (1) · Ascorbic Acid (1) · Bosentan (1) · Capsules (1) · Cardiac Resynchronization Therapy Devices (1) · Cardiac Surgical Procedures (1) · Dexmedetomidine (1) · Insulin (1)
Shandong Suncadia Medicine Co., Ltd. (3) · Viacor (3) · Abbott Medical Devices (2) · Astana Medical University (2) · Bristol-Myers Squibb (2) · MyoKardia, Inc. (2) · National Heart, Lung, and Blood Institute (NHLBI) (2) · Xijing Hospital (2) · 4Tech Cardio Ltd. (1) · Apica Cardiovascular Limited (1) · Athena Zuppa (1) · Celltrion (1) · Centre Hospitalier Universitaire Vaudois (1) · Corxel Pharmaceuticals (1) · Cytokinetics (1)
United States (18) · China (8) · United Kingdom (5) · Germany (4) · Canada (2) · France (2) · Georgia (2) · Italy (2) · Kazakhstan (2) · Netherlands (2) · South Korea (2) · Switzerland (2) · Brazil (1) · Denmark (1) · Egypt (1)
Alibek Kh Mustafin, Professor (2) · Jonathan C Fox, MD, PhD (2) · Adam A Berman, MD (1) · Ali J. Marian, MD (1) · Amr Zaher, M.D. (1) · Antonio Colombo, MD (1) · Athena Zuppa, MD, MSCE (1) · Barry Greenberg, MD (1) · Christina Vassileva, M.D. (1) · Dinghua Yi, MD (1) · Donald F Brophy, PharmD (1) · Francis Duhay, MD (1)
PMID 39302117, PMID 11794168, PMID 17543250, PMID 19142552, PMID 19329766, PMID 19679246, PMID 21422390, PMID 21492763, PMID 23580745, PMID 23633132, PMID 27989885, PMID 29540445, PMID 29932345, PMID 30846083, PMID 30944029, PMID 31975494, PMID 32718702, PMID 33481401, PMID 36061336, PMID 36288619, PMID 37680714, PMID 39014868, PMID 39556016, PMID 39989354, PMID 42160017, PMID 9033300
2015 (1), 2018 (1), UL1RR024150 (1)